# BIOlogics in Severe Nasal POlyposis SurvEy.: a French Registry

> **NCT06501807** · NA · RECRUITING · sponsor: **University Hospital, Lille** · enrollment: 900 (estimated)

## Conditions studied

- Rhinosinusitis Chronic
- Nasal Polyps

## Interventions

- **DRUG:** Biologic treatments available in Chronic Rhinosinusitis with Nasal Polyps (dupilumab, mepolizumab and benralizumab according to their marketing approval).

## Key facts

- **NCT ID:** NCT06501807
- **Lead sponsor:** University Hospital, Lille
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-11
- **Primary completion:** 2034-09-02
- **Final completion:** 2035-01-02
- **Target enrollment:** 900 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06501807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06501807, "BIOlogics in Severe Nasal POlyposis SurvEy.: a French Registry". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06501807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*